STX 478
Alternative Names: ST-814; STX-478; STX-H1047-PI3Ka inhibitors - Scorpion TherapeuticsLatest Information Update: 22 Feb 2024
At a glance
- Originator Scorpion Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 05 Dec 2023 Pharmacodynamics data from preclinical trial in Cancer presented at the 46th Annual San Antonio Breast Cancer Symposium Session (SABCS-2023)
- 17 Apr 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Spain (PO) (NCT05768139)
- 17 Apr 2023 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Spain (PO) (NCT05768139)